RxDoctor Payments Data

Garima Arora, MD

Cardiovascular Disease · Birmingham, ALNPI 1407084874

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $20,125 of the $26,483 with a category attached, or 76.0%. Boston Scientific accounts for 76.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $14,087 and has fallen 54.7% since, to $6,377 in 2025. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,483in general payments, 2019–2025

Across 92 payments — averaging $287.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$20K
  • Abbott$5K
  • E.r. Squibb & Sons, L.L.C.$510
  • AstraZeneca$175
  • Alnylam Pharmaceuticals Inc.$121
  • Bridgebio Pharma, Inc.$119
  • plus $253 from 7 others

What the payments were for

  • Consulting fees$1,0004%
  • Speaking & faculty fees$20,12576%
  • Travel & lodging$2,65210%
  • Food & beverage$2,69310%
  • Education$130%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,483 in reported general payments places this provider in the 90th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$68,239
Medicare patients
509
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan124$119,814
CamzyosMavacamten12$104,641
JardianceEmpagliflozin43$49,216
EliquisApixaban35$33,628
Praluent PenAlirocumab21$10,674
FarxigaDapagliflozin Propanediol17$9,763
XareltoRivaroxaban12$6,370
Losartan Potassium74$996
Metoprolol Succinate38$703
Rosuvastatin Calcium27$668
Isosorbide Mononitrate ErIsosorbide Mononitrate44$475
Carvedilol30$411
Atorvastatin Calcium30$390
Metoprolol Tartrate29$255
Amlodipine Besylate27$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$510$104,64112 claims
PfizerEliquis$27$33,62835 claims
AstraZenecaFarxiga$175$9,76317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →